# A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers

> **NCT02166398** · PHASE1 · COMPLETED · sponsor: **Korea United Pharm. Inc.** · enrollment: 46 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** UI15AML055MT
- **DRUG:** Amosartan 5/50

## Key facts

- **NCT ID:** NCT02166398
- **Lead sponsor:** Korea United Pharm. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02166398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02166398, "A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02166398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*